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Abstract 
 
The incidence of prostate cancer (PC) has increased by 4.6% annually in Sweden during the 
past ten years. Today’s clinically used prognostic markers are not accurate enough to separate 
the potentially life-threatening tumours from the insignificant ones in 50-80% of newly 
diagnosed PCs.  
Curative treatment of all men with early PC results in substantial overtreatment and 
subsequently a large number of men would suffer from the side effects of this treatment. 
There is an urgent need for more accurate prognostic tools to distinguish the insignificant PC 
from the potentially lethal PC in its early stage. 
 
We studied whether an initial period of surveillance in these patients might decrease their 
chance of cure by radical prostatectomy.  
The prognostic significance of tumour vascularity (TVC) from biopsy was evaluated.  
The outcome in 270 consequent screening-detected PC patients under active surveillance was 
studied and PSA doubling time (PSADT) as a predictor of outcome was evaluated.  
The proliferation marker Ki-67 was evaluated as a prognostic marker.  
The factors that influence the variations in PSADT were explored in the entire cohort in the 
screening study and in the men with PC. 
 
The results revealed that up to two years of surveillance in patients with early PC did not 
reduce the chance of cure by radical prostatectomy.  
TVC and Ki.67 were both significantly correlated to PSA relapse after prostatectomy. 
However, these markers could not improve the prognostic information generated from 
routinely used markers. 
Some 61% of patients were treatment-free after a follow-up period of 63 months in the active 
surveillance cohort. No patient has developed bone metastasis or died from PC. Fourteen 
patients died for reasons other than PC during the follow-up. PSADT was the only significant 
predictor of PSA relapse after radical prostatectomy in this cohort of patients.  
PSADT is mainly influenced by prostate volume and the presence of high-grade PC. 
 
The active surveillance approach offers an alternative to active treatment in patients with 
early-detected, low-stage, low-grade PC. PSADT seems to be a useful, reliable and 
discriminating prognostic marker of disease progression and active treatment during the 
follow-up of patients with screening-detected early PC who opt for the active surveillance 
strategy. 
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